FOLH1 and prostate carcinoma: With the approval of three PSMA-PET pharmaceuticals in recent years13,20,21, PSMA-PET has become the mainstay for diagnostic imaging in patients with prostate cancer, particularly in the recurrence setting, and is recommended by national and international guidelines14,16,22.